Barry Simon Sells 10,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $9.25, for a total value of $92,500.00. Following the completion of the sale, the director directly owned 3,081,604 shares in the company, valued at approximately $28,504,837. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ImmunityBio Price Performance

IBRX stock traded up $1.72 on Tuesday, reaching $11.55. 82,882,982 shares of the company traded hands, compared to its average volume of 31,529,002. The firm has a fifty day simple moving average of $4.82 and a 200-day simple moving average of $3.24. The company has a market cap of $11.38 billion, a P/E ratio of -30.39 and a beta of 0.16. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $12.28.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. On average, sell-side analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current year.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after purchasing an additional 29,297 shares during the period. CWM LLC lifted its stake in shares of ImmunityBio by 849.2% in the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock worth $129,000 after purchasing an additional 43,583 shares during the period. Dillon & Associates Inc. purchased a new position in shares of ImmunityBio in the second quarter worth approximately $68,000. Rathbones Group PLC grew its position in ImmunityBio by 21.5% during the second quarter. Rathbones Group PLC now owns 117,420 shares of the company’s stock valued at $310,000 after buying an additional 20,800 shares during the period. Finally, Summit X LLC purchased a new stake in ImmunityBio during the second quarter valued at approximately $28,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IBRX has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Jefferies Financial Group raised their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. HC Wainwright boosted their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday. BTIG Research lifted their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, Piper Sandler boosted their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.60.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.